Research peptides · For laboratory and scientific research in vitro · Not medications · Not approved for consumption · Adults only (18+)
Liraglutide (GLP-1 analog)
In plain language
The first modern analog approved for chronic obesity treatment (Saxenda) and type 2 diabetes (Victoza). ~13-hour half-life, daily s.c. administration.
For researchers
Binds receptors in the pancreas, brain and stomach. Enhances glucose-dependent insulin release, suppresses glucagon and slows gastric emptying, leading to reduced appetite.
Scientific literature
Other peptides
Information about Liraglutide is based on published scientific research and is intended for research purposes. Not medical advice.
Products related to this peptide are for in vitro laboratory research only. Not approved for human consumption.